<DOC>
	<DOC>NCT01965613</DOC>
	<brief_summary>The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.</brief_summary>
	<brief_title>A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Age: â‰¥18 2. History of pyoderma gangrenosum with or without other systemic disease. 1. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 halflives, whichever is longer). 2. Treatment with corticosteroids or cyclosporine within the last 2 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
</DOC>